The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Research Report 2025
Synopsis
Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.
Inattention means a person wanders off task, lacks persistence, has difficulty sustaining focus, and is disorganized; and these problems are not due to defiance or lack of comprehension.
Hyperactivity means a person seems to move about constantly, including in situations in which it is not appropriate; or excessively fidgets, taps, or talks. In adults, it may be extreme restlessness or wearing others out with constant activity.
Impulsivity means a person makes hasty actions that occur in the moment without first thinking about them and that may have a high potential for harm, or a desire for immediate rewards or inability to delay gratification. An impulsive person may be socially intrusive and excessively interrupt others or make important decisions without considering the long-term consequences.
The global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics in Pediatric and Adolescents is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics include Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB and Takeda, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics.
Report Scope
The Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GSK
Eli Lilly
Novartis
Johnson & Johnson
Mallinckrodt
Hisamitsu
UCB
Takeda
Purdue Pharma
Impax Laboratories
Segment by Type
Stimulants
Non-stimulants
Segment by Application
Pediatric and Adolescents
Adults
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Attention-deficit/hyperactivity disorder (ADHD) is a disorder marked by an ongoing pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning or development.
Inattention means a person wanders off task, lacks persistence, has difficulty sustaining focus, and is disorganized; and these problems are not due to defiance or lack of comprehension.
Hyperactivity means a person seems to move about constantly, including in situations in which it is not appropriate; or excessively fidgets, taps, or talks. In adults, it may be extreme restlessness or wearing others out with constant activity.
Impulsivity means a person makes hasty actions that occur in the moment without first thinking about them and that may have a high potential for harm, or a desire for immediate rewards or inability to delay gratification. An impulsive person may be socially intrusive and excessively interrupt others or make important decisions without considering the long-term consequences.
The global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics in Pediatric and Adolescents is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics include Pfizer, GSK, Eli Lilly, Novartis, Johnson & Johnson, Mallinckrodt, Hisamitsu, UCB and Takeda, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics.
Report Scope
The Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GSK
Eli Lilly
Novartis
Johnson & Johnson
Mallinckrodt
Hisamitsu
UCB
Takeda
Purdue Pharma
Impax Laboratories
Segment by Type
Stimulants
Non-stimulants
Segment by Application
Pediatric and Adolescents
Adults
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Stimulants
1.2.3 Non-stimulants
1.3 Market by Application
1.3.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pediatric and Adolescents
1.3.3 Adults
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Perspective (2019-2030)
2.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Trends by Region
2.2.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Dynamics
2.3.1 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Industry Trends
2.3.2 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers
2.3.3 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Challenges
2.3.4 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Revenue
3.1.1 Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue
3.4 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio
3.4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2023
3.5 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players Head office and Area Served
3.6 Key Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product Solution and Service
3.7 Date of Enter into Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Breakdown Data by Type
4.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Breakdown Data by Application
5.1 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)
6.2 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024)
6.4 North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)
7.2 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024)
7.4 Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)
9.2 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.1.4 Pfizer Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 GSK
11.2.1 GSK Company Detail
11.2.2 GSK Business Overview
11.2.3 GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.2.4 GSK Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.2.5 GSK Recent Development
11.3 Eli Lilly
11.3.1 Eli Lilly Company Detail
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.3.4 Eli Lilly Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.3.5 Eli Lilly Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.4.4 Novartis Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.5.4 Johnson & Johnson Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.5.5 Johnson & Johnson Recent Development
11.6 Mallinckrodt
11.6.1 Mallinckrodt Company Detail
11.6.2 Mallinckrodt Business Overview
11.6.3 Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.6.4 Mallinckrodt Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.6.5 Mallinckrodt Recent Development
11.7 Hisamitsu
11.7.1 Hisamitsu Company Detail
11.7.2 Hisamitsu Business Overview
11.7.3 Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.7.4 Hisamitsu Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.7.5 Hisamitsu Recent Development
11.8 UCB
11.8.1 UCB Company Detail
11.8.2 UCB Business Overview
11.8.3 UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.8.4 UCB Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.8.5 UCB Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.9.4 Takeda Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.9.5 Takeda Recent Development
11.10 Purdue Pharma
11.10.1 Purdue Pharma Company Detail
11.10.2 Purdue Pharma Business Overview
11.10.3 Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.10.4 Purdue Pharma Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.10.5 Purdue Pharma Recent Development
11.11 Impax Laboratories
11.11.1 Impax Laboratories Company Detail
11.11.2 Impax Laboratories Business Overview
11.11.3 Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
11.11.4 Impax Laboratories Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
11.11.5 Impax Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Stimulants
Table 3. Key Players of Non-stimulants
Table 4. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2019-2024)
Table 8. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2025-2030)
Table 10. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Trends
Table 11. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Drivers
Table 12. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Challenges
Table 13. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Restraints
Table 14. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players (2019-2024)
Table 16. Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2023)
Table 17. Ranking of Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product Solution and Service
Table 21. Date of Enter into Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2019-2024)
Table 25. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2025-2030)
Table 27. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2019-2024)
Table 29. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2025-2030)
Table 31. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 46. Pfizer Company Detail
Table 47. Pfizer Business Overview
Table 48. Pfizer Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 49. Pfizer Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 50. Pfizer Recent Development
Table 51. GSK Company Detail
Table 52. GSK Business Overview
Table 53. GSK Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 54. GSK Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 55. GSK Recent Development
Table 56. Eli Lilly Company Detail
Table 57. Eli Lilly Business Overview
Table 58. Eli Lilly Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 59. Eli Lilly Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 60. Eli Lilly Recent Development
Table 61. Novartis Company Detail
Table 62. Novartis Business Overview
Table 63. Novartis Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 64. Novartis Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 65. Novartis Recent Development
Table 66. Johnson & Johnson Company Detail
Table 67. Johnson & Johnson Business Overview
Table 68. Johnson & Johnson Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 69. Johnson & Johnson Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 70. Johnson & Johnson Recent Development
Table 71. Mallinckrodt Company Detail
Table 72. Mallinckrodt Business Overview
Table 73. Mallinckrodt Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 74. Mallinckrodt Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 75. Mallinckrodt Recent Development
Table 76. Hisamitsu Company Detail
Table 77. Hisamitsu Business Overview
Table 78. Hisamitsu Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 79. Hisamitsu Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 80. Hisamitsu Recent Development
Table 81. UCB Company Detail
Table 82. UCB Business Overview
Table 83. UCB Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 84. UCB Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 85. UCB Recent Development
Table 86. Takeda Company Detail
Table 87. Takeda Business Overview
Table 88. Takeda Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 89. Takeda Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 90. Takeda Recent Development
Table 91. Purdue Pharma Company Detail
Table 92. Purdue Pharma Business Overview
Table 93. Purdue Pharma Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 94. Purdue Pharma Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 95. Purdue Pharma Recent Development
Table 96. Impax Laboratories Company Detail
Table 97. Impax Laboratories Business Overview
Table 98. Impax Laboratories Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Product
Table 99. Impax Laboratories Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024) & (US$ Million)
Table 100. Impax Laboratories Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Stimulants Features
Figure 4. Non-stimulants Features
Figure 5. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application: 2023 VS 2030
Figure 7. Pediatric and Adolescents Case Studies
Figure 8. Adults Case Studies
Figure 9. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Report Years Considered
Figure 10. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region: 2023 VS 2030
Figure 13. Global Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players in 2023
Figure 14. Global Top Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2023
Figure 16. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)
Figure 18. United States Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)
Figure 22. Germany Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Region (2019-2030)
Figure 30. China Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)
Figure 38. Mexico Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Country (2019-2030)
Figure 42. Turkey Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Pfizer Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 45. GSK Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 46. Eli Lilly Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 47. Novartis Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 48. Johnson & Johnson Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 49. Mallinckrodt Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 50. Hisamitsu Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 51. UCB Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 52. Takeda Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 53. Purdue Pharma Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 54. Impax Laboratories Revenue Growth Rate in Attention-deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2019-2024)
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
